Jump to Navigation
Home

Main menu

  • Home
  • News
  • Markets Map
  • Sentiments
  • Topics
  • Data
  • Comments
  • Images
  • Blog
  • About

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • Discussions
  • FX Price Action: What's Next?
  • Rail Traffic Confirms That The Economy Remains Sluggish
  • Proxy firms still powerful and free
  • A tornado's heading your way: Now what?
  • Mexico cave art sheds light on tribes
  • Stephen Poloz: ‘The smartest guy in the room’
  • How to effectively complain to get results
  • Favorable Tailwinds For Carnival Cruises
  • One Statement Tells You Whether A Business Is Truly...
  • Europe May Finally Be In A Position To Surprise...

    For Pfizer, Is Taking Lipitor OTC a Good Idea?

    Thu, 08/04/2011 - 20:47 EDT - Seeking Alpha
    • MRK
    • PFE
    • Pharmalot

    By Pharmalot: On the eve of losing patent protection for its best-selling Lipitor cholesterol pill, Pfizer (PFE) is considering seeking FDA approval to sell an over-the-counter version. Whether the idea will pass regulatory muster, however, is questionable, given that the agency has previously nixed efforts by Merck (MRK) to sell an OTC version of the same type of cholesterol pill. Why? An FDA spokeswoman tells The Wall Street Journal, which first reported the story, that earlier research on proposed OTC statins has not shown that most consumers will make correct decisions about taking the drugs. On the other hand, she says the FDA is open to discussing the possibility, but a drugmaker must be ready to demonstrate that consumers will make correct decisions. In any event, an OTC version would allow Pfizer to capture some of the sales that will be lost when the Lipitor patent expires in November. In fact, PfizerComplete Story »

    • Original article
    • Login or register to post comments
     

    Related

    • Sanofi And Regeneron Move Forward On Cholesterol Drug, But Face Competition

      By Freedonia Freelance: In the cholesterol industry, there is great demand for alternatives to the statins that are currently available. This will cause a huge shift for the entire industry, and Sanofi (SNY) is one of the companies leading the charge, along with its partner Regeneron Pharmaceuticals (REGN).

    • Statins, Genomics, Patents, And Speculation

      By Dana Blankenhorn: Statin drugs have been taking a beating lately. Dr. Eric Topol, formerly a statin proponent, now has an op-ed in The New York Times questioning their efficacy, given new research linking them to an increased risk of diabetes.

    • Pfizer Stock Worth $25 Despite Lawsuits And Lipitor Patent Expiry

      By Trefis: Pfizer (NYSE:PFE) has seen its stock underperform some of its peers like Abbott Labs (NYSE:ABT) and Merck (NYSE:MRK), as the company continues to struggle with various lawsuits and complaints.

    • Pfizer Cuts Lipitor Deals To Fight Generics

      By The Burrill Report: By Michael Fitzhugh Pfizer (PFE) and prescription drug benefit managers are under fire for crafting agreements that would insulate Lipitor against competition at the expense of employers, the government, and other insurance plan sponsors.

    • Pfizer Looks to Partners as It Narrows Therapeutic Focus

      The Burrill Report submits: By Michael FitzhughPfizer (PFE), the self-proclaimed “world’s largest research-based pharmaceutical company,” will pare nearly $1.5 billion from its 2012 research and development budget as it steps up its dependence on external partnerships to supply both new innovations and cost savings.

    • Merck, Pfizer 'Wins' From Healthcare Reform Could Be Elusive

      Michael Steinberg submits:Pfizer (PFE) has repeatedly told us during the “great recession” that pharma cannot sell drugs to patients that don’t go to their doctors. This is especially true of the lifestyle drugs such as Pfizer’s Lipitor and Merck’s (MRK) Vytorin that require regular follow up.

    • High Stake Search For The Next Lipitor

      By Peter Geschek:Statins are a major tool in lowering cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver.

    • Charges, generic Lipitor cut Pfizer Q1 net 19 pct

    • Merck Discontinues Study of Experimental Anticlotting Drug: Biotech's Latest Troubles

      The Burrill Report submits: Merck (MRK) said it was discontinuing a study of its experimental anticlotting drug vorapaxar in patients with acute coronary syndrome after a data safety monitoring board reviewed safety and efficacy data and recommended the study be halted.

    • Merck’s Cholesterol Drug May Become Catalyst for Future Growth

      YCHARTS.com submits: Merck & Co. (MRK) researchers hailed an experimental cholesterol drug last month that may help the pharmaceutical giant dethrone bigger rival Pfizer (PFE) as the king of heart medicines. Merck’s anacetrapib lowers bad cholesterol, raises good cholesterol and appears to be safe, Merck says.

    Latest

    FX Price Action: What's Next?
    FX Price Action: What's Next?
    Bloomberg's Crusade Against Big Soda Will Die In Appeals Court
    How Michael Bloomberg Can Destroy The New York...

    User login

    • Create new account
    • Request new password
    • Click on the icon to sign in with your social network login or enter your Bullfax.com login

    Our Blog

    • Tata Steel, ECB, China’s car market and European Corporate Tax in Our News for Today 05/24/2013
    • Pandora: the charm might fade away
    • Japanese Market, Indian Rupee, China’s Stocks and Oil Prices in Our Daily Round-Up for 05/23/2013

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 1649.60 -0.06% FTSE: 6654.34 -0.64% Nikk.: 14612.45 0.88% DAX: 8305.32 -0.56% HSI: 22618.67 -0.23% FX: EUR/GBP: 1.1694 USD/EUR: 1.2935 JPY/USD: 101.175 Commodities: Gold: 1386.60

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • Discussions